Weight mitigation and tolerability of adjunctive topiramate in acute pediatric psychiatry: a retrospective real-world analysis
Open Access
- 22 July 2026
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Psychiatry
- Vol. 17, 1905527
Abstract
Background/objective: Psychotropic medications are often associated with significant and rapid weight gain in pediatric populations, especially second-generation antipsychotics and mood stabilizers. This was a retrospective study assessing weight gain, and tolerability of adjunctive topiramate in hospitalized child and adolescent psychiatric patients. Methods: A total of 285 inpatients were included in the study: an intervention group (n = 45) receiving adjunctive topiramate and a control group (n = 240) receiving standard care. Net weight, polypharmacy burden (chlorpromazine [CPZ] equivalent doses and other mood stabilizers) and psychiatric recovery (Global Assessment of Functioning [GAF] and Clinical Global Impression-Severity [CGI-S] scores) were measured. Hierarchical ANCOVA models were employed to disentangle the independent metabolic effects of topiramate from the confounding effects of polypharmacy. Results: The mean weight gain in the control group was significantly greater than in the topiramate group (3.3 kg vs -0.1 kg, p < 0.001). This protective metabolic effect persisted with high statistical significance even after controlling for the concurrent CPZ equivalent dose (3.1 kg advantage). Clinical recovery, measured by equivalent improvement in GAF scores and reduction in CGI-S scores, was similar for both groups. Conclusions: Adjunctive topiramate is a highly effective and safe metabolic shield in acute pediatric inpatient settings. It reduces the risk of psychotropic weight gain and can substantially reduce the need for obesogenic polypharmacy, without impeding the course of psychiatric recovery.Keywords
This publication has 13 references indexed in Scilit:
- Efficacy of topiramate in reducing second‐generation antipsychotic‐associated weight gain among children: A systematic review and meta‐analysisDiabetes, Obesity and Metabolism, 2024
- Topiramate for Weight Management in Children With Severe ObesityChildhood Obesity, 2023
- Efficacy and safety of topiramate for reducing impulsivity: A transdiagnostic systematic review and meta‐analysis of a common clinical useFundamental & Clinical Pharmacology, 2021
- Safety considerations in the psychopharmacology of pediatric bipolar disorderExpert Opinion on Drug Safety, 2019
- Topiramate, zonisamide and weight loss in children and adolescents prescribed psychiatric medicationsThe International Journal of Psychiatry in Medicine, 2015
- Weight gain and increase of body mass index among children and adolescents treated with antipsychotics: a critical reviewEuropean Child & Adolescent Psychiatry, 2013
- TopiramatePsychopharm Review, 2012
- Body Mass Indexes and Lipid Profiles in Hospitalized Children and Adolescents Exposed to Atypical AntipsychoticsJournal of Child and Adolescent Psychopharmacology, 2007
- Adjunctive Topiramate in Hospitalized Children and Adolescents with Bipolar DisordersJournal of Child and Adolescent Psychopharmacology, 2005
- Clinical experience with Topiramate to counteract neuroleptic induced weight gain in 10 individuals with autistic spectrum disordersBrain and Development, 2005